BAKER BROS. ADVISORS LP Q2 2023 Filing
Filed August 14, 2023
Portfolio Value
$17.3B
Holdings
107
Report Date
Q2 2023
Filing Type
13F-HR
All Holdings (107 positions)
| Stock | Value |
|---|---|
SGENUSDSeagen Inc. | $8.6B |
INCYIncyte Corporation | $2.3B |
ONCBeiGene, Ltd. | $2.1B |
ACADACADIA Pharmaceuticals Inc. | $1.0B |
MDGLMadrigal Pharmaceuticals, Inc. | $356.9M |
BMRNBioMarin Pharmaceutical Inc. | $330.3M |
IMCRImmunocore Holdings plc | $151.1M |
—Invitae Corporation | $135.0M |
KODKodiak Sciences Inc. | $119.4M |
AKROAkero Therapeutics, Inc. | $110.6M |
ARGXargenx SE | $109.2M |
RYTMRhythm Pharmaceuticals, Inc. | $107.2M |
REPLReplimune Group, Inc. | $106.3M |
ABCLAbCellera Biologics Inc. | $106.3M |
KYMRKymera Therapeutics, Inc. | $100.6M |
ROIVRoivant Sciences Ltd. | $95.0M |
BCRXBioCryst Pharmaceuticals, Inc. | $89.5M |
SWTXSpringWorks Therapeutics, Inc. | $78.7M |
TRDAEntrada Therapeutics, Inc. | $73.7M |
RVMDRevolution Medicines, Inc. | $72.0M |
IMTXImmatics N.V. | $65.1M |
290AChinook Therapeutics, Inc. | $55.9M |
MRTXEURMirati Therapeutics, Inc. | $50.9M |
—DICE Therapeutics, Inc. | $48.1M |
BMEABiomea Fusion, Inc. | $46.3M |
PRLDPrelude Therapeutics Inc. | $45.6M |
DNLIDenali Therapeutics Inc. | $42.9M |
KNSAKiniksa Pharmaceuticals, Ltd. | $39.6M |
CERSCerus Corporation | $39.5M |
NRIXNurix Therapeutics, Inc. | $38.8M |
RAREUltragenyx Pharmaceutical Inc. | $36.1M |
AVTEAerovate Therapeutics, Inc. | $33.7M |
1K0IGM Biosciences, Inc. | $29.1M |
XENEXenon Pharmaceuticals Inc. | $28.9M |
IMGNEURImmunoGen, Inc. | $28.7M |
—DBV Technologies S.A. | $27.8M |
VERVVerve Therapeutics, Inc. | $26.6M |
TSVT*2seventy bio, Inc. | $25.3M |
IDYAIDEAYA Biosciences, Inc. | $25.0M |
STOKStoke Therapeutics, Inc. | $22.6M |
BCYCBicycle Therapeutics plc | $21.5M |
GLUEMonte Rosa Therapeutics, Inc. | $20.7M |
CABACabaletta Bio, Inc. | $20.6M |
KRYSKrystal Biotech, Inc. | $19.9M |
SMMTSummit Therapeutics Inc. | $15.8M |
ANABAnaptysBio, Inc. | $15.8M |
PRMEPrime Medicine, Inc. | $15.1M |
PACBPacific Biosciences of California, Inc. | $15.0M |
RLAYRelay Therapeutics, Inc. | $14.6M |
SPRYARS Pharmaceuticals, Inc. | $13.4M |
DAWNDay One Biopharmaceuticals, Inc. | $11.9M |
SANASana Biotechnology, Inc. | $11.9M |
COGTCogent Biosciences, Inc. | $11.6M |
—POINT Biopharma Global Inc. | $10.6M |
ADAPYAdaptimmune Therapeutics plc | $10.1M |
NVTA1EURInvitae Corporation | $10.0M |
VSTMVerastem, Inc. | $9.9M |
GONGeron Corporation | $9.8M |
HRTXHeron Therapeutics, Inc. | $9.4M |
—Athira Pharma, Inc. | $9.3M |
RNAAvidity Biosciences, Inc. | $8.9M |
—bluebird bio, Inc. | $8.2M |
FATEFate Therapeutics, Inc. | $8.0M |
ALLOAllogene Therapeutics, Inc. | $7.8M |
OPTEYOpthea Limited | $7.5M |
IM8NInsmed Incorporated | $7.2M |
TCRXTScan Therapeutics, Inc. | $7.0M |
WHWKAadi Bioscience, Inc. | $6.8M |
SERASera Prognostics, Inc. | $5.9M |
ALECAlector, Inc. | $5.8M |
CMPXCompass Therapeutics, Inc. | $5.0M |
NTRANatera, Inc. | $4.9M |
MGNXMacroGenics, Inc. | $4.8M |
MREOMereo BioPharma Group PLC | $4.7M |
VSAREURAravive, Inc. | $4.1M |
—Affimed N.V. | $3.9M |
HOOKGBPHOOKIPA Pharma Inc. | $3.9M |
EWTXEdgewise Therapeutics, Inc. | $3.9M |
GRCLGracell Biotechnologies Inc. | $3.8M |
CYPHLeap Therapeutics, Inc. | $3.7M |
TLISTalis Biomedical Corporation | $3.7M |
IPSCCentury Therapeutics, Inc. | $3.6M |
—Mersana Therapeutics, Inc. | $3.6M |
BCELAtreca, Inc. | $3.5M |
—Neoleukin Therapeutics, Inc. | $3.2M |
DSGNDesign Therapeutics, Inc. | $3.1M |
XNCRXencor, Inc. | $3.1M |
TILInstil Bio, Inc. | $2.9M |
TNGXTango Therapeutics, Inc. | $2.5M |
PCVXVaxcyte, Inc. | $2.4M |
698Achilles Therapeutics plc | $2.4M |
VERAVera Therapeutics, Inc. | $2.4M |
PRAXPraxis Precision Medicines, Inc. | $2.2M |
ALGSAligos Therapeutics, Inc. | $2.0M |
PMVPPMV Pharmaceuticals, Inc. | $2.0M |
5E7iTeos Therapeutics, Inc. | $2.0M |
VORVor Biopharma Inc. | $2.0M |
KALAKala Pharmaceuticals, Inc. | $1.7M |
ISREURPerspective Therapeutics, Inc. | $1.5M |
AGLEUSDAeglea BioTherapeutics, Inc. | $1.5M |
Page 1 of 2Next